Silverarc Capital Management, LLC Otonomy, Inc. Transaction History

Silverarc Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	SELL	$1.72 - $2.51 $285,712 - $416,941	-166,112 Reduced 13.76%	1,041,273 $2.17 Million
Q1 2022 May 13, 2022	BUY	$1.72 - $2.47 $13,022 - $18,700	7,571 Added 0.63%	1,207,385 $2.9 Million
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.31 $308,874 - $422,189	182,766 Added 17.97%	1,199,814 $2.5 Million
Q3 2021 Nov 15, 2021	BUY	$1.22 - $2.2 $77,609 - $139,950	63,614 Added 6.67%	1,017,048 $1.95 Million
Q2 2021 Aug 16, 2021	BUY	$2.06 - $2.67 $1.45 Million - $1.88 Million	702,439 Added 279.86%	953,434 $2.13 Million
Q1 2021 May 18, 2021	SELL	$2.49 - $6.23 $32,260 - $80,715	-12,956 Reduced 4.91%	250,995 $640,000
Q4 2020 Feb 16, 2021	BUY	$3.48 - $6.47 $918,549 - $1.71 Million	263,951 New	263,951 $1.71 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.